Provided by Tiger Trade Technology Pte. Ltd.

INNOCARE

15.510
+1.97014.55%
Volume:25.00M
Turnover:378.76M
Market Cap:27.41B
PE:34.91
High:15.670
Open:13.530
Low:13.380
Close:13.540
52wk High:20.180
52wk Low:9.650
Shares:1.77B
HK Float Shares:1.49B
Volume Ratio:3.82
T/O Rate:1.67%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.444
ROE:12.77%
ROA:4.28%
PB:3.06
PE(LYR):34.91
PS:8.43

Loading ...

China's InnoCare Pharma H1 Revenue Surges, Partly on Orelabrutinib Growth

Reuters
·
Aug 24

INNOCARE Posts Interim Results with Profit Turnaround on Adjusted Basis

Stock News
·
Aug 24

InnoCare Schedules 24 Aug 2026 Board Meeting to Review 1H 2026 Interim Results

Bulletin Express
·
Aug 11

Why InnoCare Pharma (SEHK:9969) Is Up 12.9% After Dual Breakthrough Therapy Wins in Cancer and Autoimmune Disease - And What's Next

Simply Wall St.
·
Aug 10

Movement Alert|INNOCARE Rises 5.17% in Regular Trading, Multiple Autoimmune Pipeline Clinical Milestones Driving Sustained Uptrend

Market Focus
·
Aug 10

InnoCare Pharma (SEHK:9969) Following Breakthrough Therapy News And The Undervalued Narrative

Simply Wall St.
·
Aug 07

InnoCare Issues 2.04 Million A-Shares Under Incentive Plan, Lifting Total Outstanding to 1.77 Billion

Bulletin Express
·
Aug 05

Breakthrough Psoriasis Data For Oral TYK2 Drug Might Change The Case For Investing In InnoCare Pharma (SEHK:9969)

Simply Wall St.
·
Jul 29

InnoCare Pharma's Phase III Trial of Fadeucravacitinib Meets Primary Endpoint

MT Newswires Live
·
Jul 28

Hong Kong Stock Market Preview: Disease Prevention 15th Five-Year Plan Issued, SK Hynix Breaches IPO Price on Wall Street

Stock News
·
Jul 28

Movement Alert|InnoCare Pharma Falls 5.04% in Regular Trading, Biotech Sector Sell-Off Compounds Post-Catalyst Profit-Taking

Market Focus
·
Jul 17

InnoCare Pharma's Phase II Study of Vitiligo Drug Shows Consistent Safety, Efficacy

MT Newswires Live
·
Jul 16

Innocare's TYK2 Inhibitor Soficitinib Meets Primary Endpoint in Phase II Vitiligo Study

Stock News
·
Jul 16

Phase III Trial for Innocare's Atopic Dermatitis Drug Meets Primary Endpoint

Stock News
·
Jul 15

Movement Alert|InnoCare Pharma Rises 5.09% in Regular Trading, Biotech Sector Rallies as CDH17 ADC Clinical Data Published

Market Focus
·
Jul 15

InnoCare Pharma (SEHK:9969) Is Up 6.6% After First CDH17 ADC Enters Human Trials

Simply Wall St.
·
Jul 14

Is InnoCare Pharma (SEHK:9969) Undervalued On Its Breakthrough Lupus Trial Results?

Simply Wall St.
·
Jul 11

Movement Alert|InnoCare Pharma Rises 5.07% in Regular Trading, HK Innovative Drug Sector Rallies as ADC Pipeline Advances

Market Focus
·
Jul 10

Innocare Pharma Shares Advance with Robust Quarterly Earnings Growth

Deep News
·
Jul 09

Hong Kong Market Closes Higher, Healthcare and Tech Stocks Lead Gains While AI Hardware Sector Plunges

Stock News
·
Jul 06